login
  Password reminder
NeuroNews
Contact the editor Visit NeuroNews Twitter feed Visit NeuroNews Facebook page
 

First patient enrolled in SCAFFOLD clinical study for carotid stenting


Thursday, 12 Sep 2013 10:09
Claudio Schönholz
Claudio Schönholz

Gore has announced that it has enrolled the first patient in its Carotid stent clinical study for the treatment of carotid artery stenosis in patients at increased risk for adverse events from carotid endarterectomy (SCAFFOLD). The patient was successfully treated by Claudio Schönholz and his team at the Medical University of South Carolina in Charleston, USA.


“The first procedure using the Gore carotid stent was successful and the patient is doing well, having left the hospital the next day. Studies like this will further our understanding of optimal patient outcomes in carotid artery stenosis,” Schönholz said. “The new Gore device is designed to be flexible, offer plaque retention and stabilisation benefits, and along with bound heparin may provide advantages for improved patient outcomes.”

SCAFFOLD is a multicentre, single-arm, prospective study comparing the Gore carotid stent to a performance goal developed from carotid endarterectomy outcomes. The investigational study will include up to 50 sites in the US and will enrol approximately 312 patients. Co-principal investigators are Peter Schneider, Kaiser Permanente Medical Center, Honolulu; and William Gray, Columbia University Medical Center, New York.

“In times of uncertainty regarding optimal treatment for patients with high surgical risks, it is important to evaluate unique treatment options,” said Schneider.

Leveraging more than 35 years of clinical experience with expanded polytetrafluoroethylene (ePTFE), the Gore carotid stent is a next-generation device designed to integrate innovative material to trap arterial plaque against the vessel wall, while yielding maximised flexibility of the stent in order to conform to the often tortuous anatomy of carotid vasculature. The new Gore device combines the flexible properties of a traditional open-cell, nitinol stent design with a 500 micron pore size ePTFE lattice which offers the plaque retention and stabilisation benefits traditionally seen in a closed cell stent design. Additionally, the permanently bound heparin may offer a local advantage seen with other Gore devices that utilise bound heparin.

“Gore is committed to continuing development of innovative solutions for patients in order to improve their quality of life,” said Ben Beckstead, associate with the Gore Medical Division Peripheral Interventional Business. “The Gore SCAFFOLD clinical study will bring us one step closer to a new solution for improving patient outcomes, while simultaneously generating data for consideration of Medicare reimbursement for such procedures.”




Add New Comment

Related Items


Most popular


Written emergency stroke care protocols may improve hospital performance
Wednesday, 06 Aug 2014
New data presented at the Society of NeuroInterventional Surgery (SNIS) 11th Annual Meeting in (28 –31, Colorado Springs, USA) helps prove that written care protocols can significantly improve the ... Written emergency stroke care protocols may improve hospital performance

Wednesday, 20 Aug 2014
A University of Utah team discovered a method for turning a small, US$40 needle into a 3D microscope capable of taking images up to 70 times smaller than the width of a human hair. Utah team invents way to image brains of mice using small needle

Revive SE thrombectomy device approved in China, South Korea and Taiwan
Monday, 08 Sep 2014
The Revive SE Device from Codman Neuro is designed to ease navigation through small and tortuous blood vessels and arteries in the cerebral vasculature. The new device enables rapid restoration of ... Revive SE thrombectomy device approved in China, South Korea and Taiwan

Features


Neuro-oncologic treatment for glioblastoma
Monday, 21 Jul 2014
Malignant gliomas are the most common type of primary malignant brain tumour, accounting for 80% of patients and an annual incidence of 5.26 per 100,000 population, or 17,000 new cases diagnosed per ... Neuro-oncologic treatment for glioblastoma

Early brain stimulation may help stroke survivors recover language function
Monday, 21 Jul 2014
Dieter Heiss, who presented on early brain stimulation for stroke patients at the 8th World Congress on Controversies in Neurology (CONy), 8–11 May, Berlin, Germany, writes for NeuroNews on how this ... Early brain stimulation may help stroke survivors recover language function

Profiles


Vladimír Beneš Jr
Tuesday, 30 Sep 2014
Vladimír Beneš Jr is professor and chair at the First Medical School, Charles University, P... Vladimír Beneš Jr

Mauricio Castillo
Monday, 14 Jul 2014
Mauricio Castillo is a professor of Radiology and chief, Division of Neuroradiology, University of N... Mauricio Castillo

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
 
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions